PI3K inhibitors in haematological malignancies
PI3K inhibitors in haematological malignancies
About this item
Full title
Author / Creator
Publisher
London: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Two of the three original idelalisib randomised registration trials in patients with relapsed chronic lymphocytic leukaemia showed both progression-free survival and overall survival benefits in patients who received idelalisib rather than placebo in combination;2,3 this was confirmed in long-term follow-up.3 A study published in 2021 showed improv...
Alternative Titles
Full title
PI3K inhibitors in haematological malignancies
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2696861823
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2696861823
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(22)00300-X
